Ryszard Jerzy Gryglewski

Ryszard Jerzy Gryglewski's AcademicInfluence.com Rankings

Medical

#2690

World Rank

#3121

Historical Rank

Pharmacology

#293

World Rank

#342

Historical Rank

medical Degrees

Download Badge

Medical

Ryszard Jerzy Gryglewski's Degrees

PhD Pharmacology Medical University of Gdańsk

Why Is Ryszard Jerzy Gryglewski Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ryszard Jerzy Gryglewski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Flavonoids are scavengers of superoxide anions. (1988) (1359)
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. (1972) (459)
Optical Projection Tomography as a Tool for 3D Microscopy and Gene Expression Studies (2002) (398)
Generation of prostacyclin by lungs in vivo and its release into the arterial circulation (1978) (377)
Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. (1977) (340)
Mediators Produced by the Endothelial Cell (1988) (330)
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. (1989) (305)
Flavonoids are scavengers of superoxide anions (1988) (303)
The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits. (1977) (282)
Prostacyclin and thromboxane A2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. (1978) (255)
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. (1988) (250)
Bioactivity of flavonoids. (1996) (212)
Gastric cytoprotection by epidermal growth factor: Role of endogenous prostaglandins and DNA synthesis (1981) (171)
Prostacyclin among prostanoids. (2008) (153)
Role of prostaglandins in the formation of aspirin-induced gastric ulcers (1981) (142)
The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. (1987) (106)
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti‐inflammatory drugs (1972) (104)
Prostaglandins, platelets, and atherosclerosis. (1980) (98)
Experimental atherosclerosis in rabbits: platelet aggregation, thromboxane A2 generation and anti-aggregatory potency of prostacyclin. (1977) (97)
Gastric cytoprotection by epidermal growth factor. Role of endogenous prostaglandins and DNA synthesis. (1981) (94)
Low density lipoproteins (LDL) are carriers for lipid peroxides and inhibit prostacyclin (PGI2) biosynthesis in arteries. (1980) (91)
Anti-platelet action of intravenous infusion of prostacyclin in man. (1978) (83)
Role of prostaglandins in the formation of aspirin-induced gastric ulcers. (1981) (80)
Prostacyclin and Its Stable Analogue Iloprost (1987) (79)
The endothelial cell as a metabolic and endocrine organ (1987) (73)
De-aggregatory action of prostacyclin in vivo and its enhancement by theophylline. (1978) (68)
Prostacyclin formation by myometrial & decidual fractions of the pregnant rat uterus. (1978) (65)
Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro. (1999) (65)
The generation from arachidonic acid of rabbit aorta contracting substance (RCS) by a microsomal enzyme preparation which also generates prostaglandins (1972) (63)
Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation. (2001) (62)
The effect of 4-acetamidophenol on prostaglandin synthetase activity in bovine and ram seminal vesicle microsomes. (1978) (61)
Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. (2005) (59)
Effect of Prostacyclin on Fibrinolytic Activity in Patients with Arteriosclerosis Obliterans (1982) (56)
Nitric oxide from polymorphonuclear leukocytes modulates red blood cell deformability in vitro. (1993) (55)
The inactivation of noradrenaline and isoprenaline in dogs (1970) (49)
The role of nitric oxide in regulation of deformability of red blood cells in acute phase of endotoxaemia in rats. (1997) (47)
Prostacyclin, Nitric Oxide, and Atherosclerosis a (1994) (44)
Antioxidant properties of some chemicals vs their influence on cyclooxygenase and lipoxidase activities. (1983) (42)
Synthesis and Properties of 2-Carboxyalkyl-1,2-benzisoselenazol-3(2H)-ones and Related Organoselenium Compounds as Nitric Oxide Synthase Inhibitors and Cytokine Inducers (1996) (42)
Reversal of platelet aggregation by prostacyclin. (1978) (41)
Comparison of Endothelial Pleiotropic Actions of Angiotensin Converting Enzyme Inhibitors and Statins (2001) (41)
Prostacyclin and atherosclerosis (1979) (39)
Protective role of pulmonary nitric oxide in the acute phase of endotoxemia in rats. (1998) (39)
Interactions between nitric oxide and prostacyclin. (1993) (38)
A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation. (1978) (38)
The effect of prostacyclin and nitric oxide on deformability of red blood cells in septic shock in rats. (1996) (37)
Morphine antagonises prostaglandin E1- mediated inhibition of human platelet aggregation (1975) (37)
Interactions between endothelial mediators. (1995) (37)
Modulation of the pharmacological actions of nitrovasodilators by methylene blue and pyocyanin (1992) (35)
Acetate metabolism in brain mechanisms of adaptation to ethanol. (2003) (32)
Umbilical arteries of babies born to cigarette smokers generate less prostacyclin and contain less arginine and citrulline compared with those of babies born to control subjects. (1995) (30)
Prostacyclin and thromboxane generating systems in rabbits pretreated with aspirin. (1978) (30)
Antiaggregatory effects of flavonoids in vivo and their influence on lipoxygenase and cyclooxygenase in vitro. (1984) (29)
Mesoionic oxatriazole derivatives--a new group of NO-donors. (1994) (28)
In vivo method for quantitation of anti-platelet potency of drugs (1978) (28)
Eicosanoids, Aspirin, and Asthma (1998) (27)
Rabbit-aorta contracting substance (RCS) may be a prostaglandin precursor. (1971) (27)
Bradykinin as a major endogenous regulator of endothelial function. (2002) (26)
Cyanonitrosylmetallates as potential NO-donors. (1998) (24)
Fibrinolytic Activity of 6-Keto-Prostaglandin E1 (1983) (23)
Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. (1996) (22)
Molecular mechanisms of inflammation. (1981) (22)
A potent inhibitor of thromboxane A2 biosynthesis in aggregating human blood platelets. (1977) (22)
The fibrinolytic activity of N-arylanthranilates. (1966) (21)
Pharmacology of vascular endothelium (2005) (21)
Nitric oxide : basic research and clinical applications (2001) (21)
The lung as a generator of prostacyclin. (1980) (21)
The influence of saturated fatty acids on prostaglandin synthetase activity. (1975) (21)
Interaction Between NO Donors and Iloprost in Human Vascular Smooth Muscle, Platelets, and Leukocytes (1989) (20)
A release of prostaglandins may be responsible for acute tolerance to norepinephrine infusions. (1974) (19)
Interactions between human platelets and eosinophils are mediated by selectin-P. (2002) (19)
Selectin-P-mediated adherence of platelets to neutrophils is regulated by prostanoids and nitric oxide. (1993) (19)
Asthma and anti-inflammatory drugs. Mechanisms and clinical patterns. (1983) (18)
Angiotensin-induced release of prostacyclin (PGI2) into circulation of anaesthetized cats. (1979) (18)
Prostaglandin E2 in gastric mucosa and its role in the prevention of ulcers induced by acetyl salicylic acid in cats. (1981) (17)
Aspirin Sensitivity: Other Drugs (1975) (16)
Interactions between endothelial secretogogues. (1995) (16)
The effect of nitric oxide donors on the release of plasminogen activator inhibitor (PAI) from rabbit platelets in vitro. (1995) (16)
In vivo endothelial interaction between ACE and COX inhibitors. (2005) (15)
Statins rise cytoplasmic calcium level [Ca2+]i in cultured endothelial cells. (2004) (14)
Interaction between stimulators of adenylate and guanylate cyclases in human leukocytes, platelets and arteries. (1989) (14)
NG-hydroxy-L-arginine and hydroxyguanidine potentiate the biological activity of endothelium-derived relaxing factor released from the rabbit aorta. (1992) (14)
Prostaglandins and aspirin-sensitive asthma. (2015) (13)
Cytoprotection of human polymorphonuclear leukocytes by stimulators of adenylate and guanylate cyclases. (1989) (13)
Inhibition of prostacyclin formation by lipid peroxides in the arterial wall: hypothetical step in development of atherosclerosis. (1978) (13)
The Impact of Prostacyclin Studies on the Development of Its Stable Analogues (1987) (12)
Screening for inhibitors of prostaglandin and thromboxane biosynthesis. (1978) (12)
Nitric oxide donors as generators and scavengers of superoxide anions. (1993) (12)
Hypoxic pulmonary vasoconstriction in isolated blood-perfused rat lung; modulation by thromboxane A2, platelet-activating factor, cysteinyl leukotrienes and endothelin-1. (2002) (11)
Effect of L-arginine on plasminogen-activator inhibitor in hypertensive patients with hypercholesterolemia. (1993) (11)
Unusual effects of aspirin on ticlopidine induced thrombolysis (2000) (11)
Prostaglandins in therapy of cardiovascular disease. (1985) (10)
Fibrinolytic Activity of some Biarylcarboxylic Acids (1967) (10)
Conversion of exogenous arachidonic acid to prostaglandins in the pulmonary circulation in vivo. A human and animal study. (1981) (9)
Endothelial nitric oxide, prostacyclin (PGI2) and tissue plasminogen activator (t-PA): alliance or neutrality? (1995) (9)
Endothelial control of coronary flow in perfused guinea pig heart (1995) (9)
BRADYKININ AS A MAJOR ENDOGENOUS REGULATOR OF ENDOTHELIAL FUNCTION (2002) (9)
Mesoionic oxatriazoles (MOTA): NO-donating characteristics and pharmacology. (2002) (8)
The influence of propranolol, INPEA, iproveratril and some 1-naphthylethylamine derivatives on the myocardial phosphorylase activity. (1970) (8)
Ischaemic cardiac hyperaemia: role of nitric oxide and other mediators. (1996) (8)
BIOASSAY OF HISTAMINE IN THE PRESENCE OF PROSTAGLANDINS (1976) (8)
Prostacyclin and Atherosclerosis—A Hypothesis (1980) (8)
Platelets in fibrinolytic system. (1995) (8)
Disaggregatory action of phosphodiesterase inhibitors. (1981) (7)
A biological method for studying the interaction between platelets and vascular endothelium. (1990) (7)
Nitric oxide donation and nitrite assays in the presence of thiols and albumin as determined by Griess' and Werringloer's methods. (1997) (7)
Pneumotoxicity of lipopolysaccharide in nitric oxide-deficient rats is limited by a thromboxane synthase inhibitor. (1997) (7)
Release of a prostaglandin E-like substance into mixed venous blood during endotoxin hypotension in cats. (1975) (7)
Pharmacology of vascular endothelium. Delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. (2005) (7)
Prostacyclin and nitric oxide. (1994) (7)
Prostaglandin and thromboxane biosynthesis inhibitors (2004) (6)
Binding of the membrane active drugs to bovine serum albumin and human erythrocyte membranes. (1975) (6)
Salicylates and 12-lipoxygenase activity in human washed platelets. (1986) (6)
Aspirin-induced asthma and cyclooxygenases (1998) (6)
Contribution of arachidonic acid metabolites to atherosclerosis. (1986) (6)
In vitro generation and decomposition of S-nitrosothiols from direct and indirect nitric oxide donors. (1995) (6)
Prostaglandin feedback mechanism limits vasoconstrictor action of norepinephrine in perfused rabbit ear (1975) (6)
Scavenging of superoxide anions by nitric oxide donors (1992) (6)
Prostacyclin--experimental and clinical approach. (1983) (6)
Nitric oxide complements prostacyclin in the regulation of endothelial thromboresistance under flow conditions. (1993) (6)
The influence of hydrocortisone and indomethacin on the release of prostaglandin-like substances during circulatory shock in cats, which was induced by an intravenous administration of rabbit blood. (1978) (6)
Participation of prostaglandins in pathogenesis of aspirin-sensitive asthma (2004) (6)
Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation (2004) (5)
Endogenous factors affecting arachidonic acid metabolism: I. Biosynthesis of prostacyclin and prostaglandins by carrageenin granulomas of rats (1978) (5)
Prostacyclin and atherosclerosis--experimental and clinical approaches. (1988) (5)
The Influence of Some 1-Substituted 6-Methoxy-1,2,3,4-tetrahydro-β-carbolines on the Metabolism and Activity of 5-Hydroxytryptamine (1966) (5)
Mass-spectrometric evidence for spontaneous and angiotensin-induced generation of prostacyclin by perfused cat lungs. (1980) (5)
Interactions between reactive oxygen species and sulfhydryl groups of cysteine, acetylcysteine and glutathione. (1995) (5)
Design of a new prostaglandin synthetase inhibitors in a group of N-(2-carboxyphenyl)phenoxyacetamides and their antiinflammatory activity. (1976) (4)
Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo. (2010) (4)
Effects of prostanoids on generation of superoxide ions by human neutrophils. (1987) (4)
Flavonoids — Lipoxygenases — Platelet Aggregation (1985) (4)
Influence of SIN-1 and sodium nitroprusside (NANP) on ox-LDL metabolism in macrophages. (1994) (4)
A neutrophil-derived NO-synthase (NOS) inhibitor. (1995) (4)
Sir John Robert Vane (1927–2004) (2010) (3)
A possible role of endothelial vasorelaxants in the pathogenesis of migraine (1990) (3)
On the mechanism of angiotensin II induced release of prostacyclin. (1981) (3)
Eicosanoid balance at early stages of experimental atherosclerosis. Its relationship with plasma fibrinolytic activity and platelet aggregation. (1986) (3)
pH-dependent release of EDRF from rabbit aortic endothelium. (1990) (3)
Transcellular biosynthesis of eicosanoids. (1999) (3)
Prostaglandins and Vascular Wall (1977) (3)
Organic anions which induce fibrinolysis in vitro. (1966) (3)
Almitrine increases plasma fibrinolytic activity through the release of prostacyclin from lungs into circulation. (1982) (3)
Permissive effect of molsidomine towards cardioprotective action of iloprost in myocardial ischemia in cats. (1993) (3)
In vitro and in vivo models for evaluating drugs which influence arachidonic acid metabolism. (1979) (3)
Influence of no-donor (SIN-1) on functions of inflammatory cells (2005) (3)
John R. Vane (1927–2004) (2005) (2)
A paradox of thrombogenesis by streptokinase and its prevention by iloprost and camonagrel. (1996) (2)
Pharmacological Interference in Biotransformation of Arachidonic Acid (1979) (2)
Myocardial reactive hyperaemia in perfused guinea pig heart. (1995) (2)
Prostacyclin in the treatment of atherosclerosis obliterans and other vascular diseases. (1984) (2)
Carrageenin hyperthermia in rats (1974) (2)
Influence of INPEA, pindolol and propranolol on the chronotropic and metabolic responses to -adrenergic stimulation in intact rats. (1971) (2)
PROSTACYCLIN AS AN ANTI-ATHEROSCLEROTIC HORMONE - A HYPOTHESIS (1981) (2)
Pharmacological Interference in Arachidonic Acid Cascade (1981) (2)
Cardioprotection by molsidomine and iloprost in myocardial ischemia in anaesthetized cats. (1992) (2)
Streptokinase-prostacyclin--nitric oxide: in vivo interactions. (1995) (2)
[Significance of arachidonic acid cascade in cardiology]. (1978) (1)
Metabolites of arachidonic acid in the lung. (1987) (1)
On the mechanism of thrombogenesis during pharmacological thrombolysis. (1996) (1)
Bioassay of Prostacyclin and Thromboxane A2 (1981) (1)
Eicosanoids in aspirin-induced asthma. (1989) (1)
Effects of prostacyclin in atherosclerotic vascular disease. (1985) (1)
Letter: Aspirin sensitivity: other drugs. (1975) (1)
Crossroads of L-Arginine/Arachidonate Metabolism (1997) (1)
The role of oxygen free radicals in the destruction of endothelium-derived relaxing factor (EDRF) (1987) (1)
Cellular and Humoral Markers of Tissue Damage (1996) (1)
The effect of insulin and tolbutamide on the reduced glutathione concentration in the blood of diabetic and non-diabetic persons. (1961) (1)
Secretory function of vascular endothelium and its implication in the action of vasoactive drugs. (1990) (1)
The evolution of ideas in prostaglandin research. (1980) (1)
A triple test for screening biological activity of prostacyclin analogues (1978) (1)
[Pharmacological research on the structure of adrenergic receptors in the heart]. (1972) (0)
[Recent views on the metabolism of biogenic amines]. (1960) (0)
Interaction between prostacyclin and nitric oxide TN white blood cells (1990) (0)
[Mechanisms regulating the release of deaggregating prostanoids]. (1982) (0)
[Effect of a series of indole derivatives on monoamine oxidase activity]. (1971) (0)
PROSTACYCLIN - CLINICAL IMPLICATIONS OF BIOLOGICAL ACTIONS1 (1980) (0)
20-Methyl-prostacyclin analogs--a two stage screening procedure for biological properties. (1978) (0)
The application of ultrasounds for detection of scavenging of superoxide anions by drugs. (1991) (0)
Prostaglandins, platelets, lipids: New developments in atherosclerosis (1982) (0)
The Endothelium: A New Secretory Organ Target or Promoter of Pathophysiological Derangements in ICU Patients (1996) (0)
Review article The role of endothelium in pharmacotherapy of diabetic angiopathies (2007) (0)
Central nervous action of alpha-aminobutyrylcholine. (1965) (0)
Interaction between prostacyclin and molsidomine in blood cells and plasma. (1991) (0)
Crossroads of medicine and chemistry in the 20th century (2007) (0)
From Hippocrates to statistics. A historical perspective (2015) (0)
On the mechanism of reactive hyperaemia in perfused guinea pig heart (1995) (0)
1139 – PROSTAGLANDINS AND PROSTAGIANDIN SYNTHESIS INHIBITORS IN ETIOLOGY AND TREATMENT OP INFLAMMATION (1977) (0)
ENDOTOXIN-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME IN NITRIC OXIDE-DEFICIENT RATS (1998) (0)
2184 – THE GENERATION OF PROSTACYCLIN BY ARTERIES AND BY THE CORONARY VASCULAR BED DURING THE DEVELOPMENT OF EXPERIMANTAL ATHEROSCLEROSIS IN RABBITS (1978) (0)
Anti-aggregatory prostanoids. Part II. (1985) (0)
The effect of tolbutamide and insulin on the reduced glutathione content of the blood and liver of normal and alloxan-diabetic rats. (1961) (0)
Synthesis and Properties of 2-Carboxyalkyl-1,2-benzisoselenazol-3(2H)- ones and Related Organoselenium Compounds as Nitric Oxide Synthase Inhibitors and Cytokine Inducers. (1997) (0)
[ROMEK. In memory of professor Roman Rembies--on the 20th anniversary of his death]. (2005) (0)
Selectin P (PADGEM GMP-140)—Mediated Adhesion of Human Platelets to Neutrophils in Vitro and the Immune Complex-induced Peritoneitis in Rats is Influenced by Interleukin-8 (1995) (0)
[Endogenous substances with high biological activity--their pharmaco-therapeutic significance]. (1976) (0)
Male portrait head (2009) (0)
In Memoriam (2013) (0)
Humoral Homeostasis — Role of Vascular Endothelium (1997) (0)
Dietary PUFAs, lipid peroxides, atherosclerosis, aspirin. (1979) (0)
Prostaglandins and the mechanism of drug action in circulatory system. (1976) (0)
[Prostacyclins and arteriosclerosis]. (1979) (0)
Changes in coronary endothelial function during progression of cardiac hypertrophy and failure in TGαq∗44 mice (2002) (0)
982 – NORA DRENALINE-INDUCED RELEASE OP PROSTAGLANDINS E FROM THE PERFUSED BLOOD VESSELS OF THE RABBIT. (1977) (0)
[New arylsulfonylurea antidiabetics]. (1957) (0)
Relations between endothelial secretogogues: Alliance or neutrality? (1995) (0)
Modulation of LDL catabolism by sodium nitroprusside and PGE2 in human peripheral blood lymphocytes. (1994) (0)
Anti-aggregatory prostanoids. Part I. (1985) (0)
[Endogenous nitroglycerin]. (1990) (0)
Prostacyclin in vascular pathology--therapeutic possibilities. (1984) (0)
Regulatory role of oxygen and lipid free radicals in the secretory function of endothelium (1987) (0)
[Medical pharmacogenetics. I. Methods applied in pharmacogenetic studies]. (1967) (0)
Unknown faces of known drugs (2008) (0)
Prostacyclin in Therapy of Vascular Disease (1985) (0)
[Prostacyclin, EDRF and arteriosclerosis]. (1989) (0)

This paper list is powered by the following services:

Ryszard Jerzy Gryglewski's Academic­Influence.com Rankings

Ryszard Jerzy Gryglewski's Degrees

Why Is Ryszard Jerzy Gryglewski Influential?

Ryszard Jerzy Gryglewski's Published Works

Published Works

Ryszard Jerzy Gryglewski's AcademicInfluence.com Rankings